Nexstim (NXTMH.HE) Stock Analysis & AI Equity Report
Nexstim (NXTMH.HE) overview
Nexstim (NXTMH.HE) stock analysis and AI equity research. For the latest completed financial year, 2024, Nexstim reported revenue of EUR 8.7m and operating profit of EUR -0.5m; the year-end share price was N/A and market capitalisation was N/A. Nexstim is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Nexstim's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-06-17. Data will be refreshed during report generation.
About Nexstim
Nexstim Plc is a Finnish medical technology company that develops and sells navigated transcranial magnetic stimulation systems for brain diagnostics, neurosurgical planning and therapy. Its NBS 6 platform and related software are used for mapping motor and language areas and for treating conditions such as major depression and chronic neuropathic pain, with sales supported by direct and partner channels.
Generate the Nexstim report
Nexstim is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Nexstim and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.